Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

1.220 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.220
Bid (Size) 1.210 (1)
Ask (Size) 1.250 (1)
Prev. Close 1.220
Today's Range 1.220 - 1.220
52wk Range 1.150 - 20.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. 
Via Benzinga
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Macatawa Bank Corporation (NASDAQ: MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corporation (NASDAQ: WFTC) and Macatawa Bank announced that they have entered into... 
Via Benzinga

Performance

YTD
-76.03%
-76.03%
1 Month
-37.11%
-37.11%
3 Month
-63.80%
-63.80%
6 Month
-77.98%
-77.98%
1 Year
-93.20%
-93.20%

More News

Read More
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
SciSparc To Acquire AutoMax, A Strategic Leap Towards Industry Diversification
Via Benzinga
SciSparc to Acquire AutoMax
From SciSparc Ltd
Via GlobeNewswire
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
From SciSparc Ltd
Via GlobeNewswire
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Via Benzinga
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
From SciSparc Ltd
Via GlobeNewswire
Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
From SciSparc Ltd
Via GlobeNewswire
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
From SciSparc Ltd
Via GlobeNewswire
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
From SciSparc Ltd
Via GlobeNewswire
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.